Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Resorberbare Scaffolds med everolimus-Eluering til Behandling af Infrapopliteal Arteriesygdom hos Patienter med Kronisk Livstruende Iskæmi (RESCUE)

REsorberbare SCaffolds med everolimus-Eluering til Behandling af Infrapopliteal Arteriesygdom hos Patienter med Kronisk Livstruende Extremitetsiskæmi

RESCUE is a Europe-wide study that will follow 400 people with critical limb-threatening ischemia (CLTI). It aims to see how well Esprit BTK™ Everolimus Eluting Resorbable Scaffolds work in real-life medical settings. The study focuses on people who have heavily calcified arteries in the infrapopliteal areas of the leg.

These drug-eluting resorbable scaffolds release a medication that helps prevent the inner wall of the blood vessel from thickening after injury or surgery. This can reduce the chance of the artery becoming blocked again (a problem called restenosis), while also giving temporary structural support to the vessel. Over time, the scaffold naturally dissolves in the body, which may lower the long-term risks associated with permanent metal stents.

Studieoversigt

Undersøgelsestype

Observationel

Tilmelding (Anslået)

400

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Claire Poulet, PhD
  • Telefonnummer: +41 79 385 16 78
  • E-mail: oracue@cirse.org

Undersøgelse Kontakt Backup

  • Navn: Dhwani S. Korde, PhD
  • Telefonnummer: +4367762942469
  • E-mail: oracue@cirse.org

Studiesteder

      • Hull, Det Forenede Kongerige, HU3 2JZ
        • Rekruttering
        • Hull University Teaching Hospitals NHS Trust
        • Ledende efterforsker:
          • Raghu Lakshminarayan, Dr

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Adult CLTI patients treated with the Esprit BTK everolimus-eluting resorbable scaffold following adequate vessel preparation for infrapopliteal artery disease.

Beskrivelse

Inclusion Criteria:

  1. Rutherford classification category ≥4;
  2. Treatment of infrapopliteal lesions with the Esprit BTK everolimus eluting resorbable scaffold system following adequate vessel preparation;
  3. Calcification of target lesions must be visible on fluoroscopy or CT-angiography;
  4. Patients competent and willing to provide informed consent.

Exclusion Criteria:

  1. Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);
  2. Inadequate inflow (>30% stenosis) following optimization;
  3. Insufficient direct outflow (less than 1 run-off vessel);
  4. Endovascular procedure(s) on the treatment site within 4 weeks before index procedure;
  5. Patients planned to receive an above ankle amputation of the target limb;
  6. Patients enrolled in ORACLE (ClinicalTrials.gov ID NCT07270562).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Adult CLTI patients with infrapopliteal calcified lesions

Adult CLTI patients planned to receive the Esprit BTK™ resorbable scaffold following pre-dilatation with angioplasty balloon.

The Esprit BTK™ is a bioresorbable vascular scaffold designed for arteries below the knee. It provides temporary support to keep the vessel open while releasing everolimus-an antiproliferative drug that helps prevent excessive tissue growth and reduces the risk of restenosis. As the scaffold delivers the medication, it gradually dissolves, potentially lowering long-term risks associated with permanent stents.

Andre navne:
  • Lægemiddelafgivende resorberbart scaffold

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of lesions free from Clinically-Driven Target Lesion Revascularization (CD-TLR)
Tidsramme: 12 months

Defined as freedom from any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion.

12 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
CD-TLR-free survival per target lesion
Tidsramme: Until the end of the follow-up period of 3 years

Defined as the time between first index procedure and any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion.

Until the end of the follow-up period of 3 years
Clinical response using Rutherford classification categories
Tidsramme: 12, 24, and 36 months

The Rutherford classification is a clinical scale used to categorize the severity of peripheral arterial disease: Category 0 = asymptomatic; Category 1 = mild claudication; Category 2 = moderate claudication; Category 3 = severe claudication; Category 4 = ischemic rest pain; Category 5 = minor tissue loss; Category 6 = severe tissue loss.

12, 24, and 36 months
Wound status
Tidsramme: 12, 24, and 36 months

Defined as healing status of the dominant ischemic wound of the target limb (complete, partial, unchanged, worsening).

12, 24, and 36 months
Freedom from major amputation of the target limb
Tidsramme: 12 and 24 months

Defined as absence of any amputation of the target limb (above ankle).

12 and 24 months
Amputation-free survival
Tidsramme: Until the end of the follow-up period of 3 years

Defined as time between first index procedure and amputation of the target limb, minor (digital, metatarsal), major below the knee or major above the knee (excluding any amputation planned before the index procedure).

Until the end of the follow-up period of 3 years
Overall survival
Tidsramme: Until the end of the follow-up period of 3 years

Defined as the time between the first index procedure and death of any cause.

Until the end of the follow-up period of 3 years
Patient-reported health-related quality-of-life
Tidsramme: Baseline, Day 0 (day of procedure), 6-, 12-, 24-, 26-months post treatment

Measured by Vascular Quality of Life Questionnaire - 6 items (VascuQol-6), which is a short patient-reported outcome measure (PROM), used to assess health-related quality of life in people with PAD. It consists of 6 questions, each scored from 1 to 7, with 1 as the worst possible quality of life and 7 as the best possible quality of life. Higher overall scores reflect better quality of life for patients with PAD.

Baseline, Day 0 (day of procedure), 6-, 12-, 24-, 26-months post treatment
Frequency and severity of procedural complications and other adverse events
Tidsramme: Within 30 days after the index procedure

Grading according to the classification system of the Cardiovascular and Interventional Radiological Society of Europe.

Within 30 days after the index procedure
Frequency of major adverse limb events (MALE) and peri-operative death (POD).
Tidsramme: 6 months for MALE; Within 30 days after the index procedure for POD

MALE include above-ankle amputation in the index limb, major re-intervention on the index limb at 6 months and POD includes perioperative (30-day) mortality.

6 months for MALE; Within 30 days after the index procedure for POD
Clinical response using ankle-brachial index (ABI)
Tidsramme: 12, 24, and 36 months

The ankle-brachial index (ABI) is a non-invasive measure calculated as the ratio of systolic blood pressure at the ankle to systolic blood pressure at the arm. ABI categories commonly used to classify peripheral arterial disease are: >1.40 = non-compressible arteries; 1.00-1.40 = normal; 0.91-0.99 = borderline; 0.41-0.90 = mild to moderate peripheral arterial disease; <0.40 = severe peripheral arterial disease.

12, 24, and 36 months
Clinical response using toe pressure
Tidsramme: 12, 24, and 36 months

The toe pressure test measures distal limb perfusion by recording systolic pressure at the toe. In CLTI patients, toe pressure ≤30 mmHg is commonly used to indicate severe ischemia, while values >30 mmHg suggest better perfusion.

12, 24, and 36 months
Clinical response using WIfi (wound, ischemia and foot infection) score
Tidsramme: 12, 24, and 36 months

The WIfI classification is a staging system used to assess CLTI based on wound extent, ischemia severity, and foot infection. Each component is graded from 0 (none) to 3 (severe). Lower WIfI scores indicate a lower risk of limb loss and a lesser urgency for revascularization, whereas higher scores indicate greater disease severity, higher amputation risk, and greater potential benefit from revascularization.

12, 24, and 36 months
Restoration of normal lumen per target lesion
Tidsramme: Immediately upon procedure completion

Defined as residual stenosis ≤30%, immediately after completion of full planned procedure.

Immediately upon procedure completion

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Studiestol: Gerd Grözinger, Prof. Dr. med., SLK Kliniken Heilbronn GmbH
  • Studiestol: Marianne Brodmann, Univ.-Prof. Dr. med., Medizinische Universität Graz
  • Studiestol: Raghu Lakshminarayan, Dr, Hull University Teaching Hospital
  • Studiestol: Stefan Müller-Hülsbeck, Prof. Dr. med., DIAKO Krankenhaus gGmBH

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

31. august 2026

Primær færdiggørelse (Anslået)

1. august 2032

Studieafslutning (Anslået)

1. december 2032

Datoer for studieregistrering

Først indsendt

19. november 2025

Først indsendt, der opfyldte QC-kriterier

26. november 2025

Først opslået (Faktiske)

8. december 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner